Entera Bio Announces $275 Million Private Placement
Entera Bio has announced the pricing of an oversubscribed private placement totaling $275 million. The offering is led by existing investor BVF Partners and includes participation from several healthcare-focused institutional investors. Under the terms, Entera will issue approximately 122.96 million ordinary shares and 11.84 million pre-funded warrants at a set purchase price. This fundraising effort reflects strong confidence in Entera Bio's business strategy and growth potential within its sector. The capital raised is expected to support ongoing operations, research initiatives, or strategic opportunities for the company.
